After having 17 melanoma spots removed, ‘Real Housewives of Beverly Hills’ alum Teddi Mellencamp was diagnosed with multiple ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

While melanoma is much less common than other types of skin cancer, it is the most serious because it is more likely to ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

Teddi Mellencamp, former cast member of "Real Housewives of Beverly Hills," has revealed that after struggling with severe ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 targeting immunotherapies.

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...